From: Role of 5-HT7 receptors in the immune system in health and disease
Cell Type | 5-HT7 Effect | |
Dendritic cells | ●Induces secretion of IL-1β and IL-8; reduces secretion of IL-12 and TNF-α ●Induces process branching and elongation | |
Monocytes, Macrophagues, Microglia | ●Pro- and anti-inflammatory ○Anti-apoptotic ○Increase in TNF-α, IL-6, Bcl-6, NF-kB ○AS-19 (agonist) decreases IL-12, TNF-α, and type 1 interferons; enhances production of TGF-β1 ○SB-269970 (antagonist) increases TNF-α and IL-12 | |
Lymphocyte | ●Concanavalin A, reserpine, and physical restrain increased expression of 5-HT7 ●Increase in proliferation rate, expression of CD25 | |
Disease Model | 5-HT7 Effect | |
Inflammatory Bowel Disease | ●5-HT7 expression increased in DSS-induced colitis ●5-HT7 blockade/ablation results in increased severity of acute and chronic colitis ●5-HT7 agonists have anti-inflammatory effect | |
Lung Injury | ●5-HT7 antagonists decrease lung fluid content, TNF-α, IL-6, oxidative stress in bleomycin-induced lung injury ●5-HT7 antagonists reduce collagen deposition, expression of TGF-β1 and procollagen type Ӏ | |
Central nervous system inflammation | ●LP-211 (agonist) reduces neurotoxic effect of β-amyloid in a model of Alzheimer disease ●AS-19 (agonist) reduces pro-apoptotic effect of streptozotocin | |
Sepsis | ●In LPS-induced sepsis, 5-HT7 mRNA increases in parallel to TNF-α, IL-1β, NF-κB ●LP-44 (agonist) attenuates cell injury and reduces iNOS and TNF-α ●In a CLP-induced sepsis, AS19 increases survival; reduces tissue injury, inflammatory cytokines, lung NF-κB | |
Liver Injury | ●5-HT7 signaling induced during chronic liver injury ○Reduced ALT and AST levels ○Increased superoxide dismutase ○Reduced TNF-α, IL-6, TGF-β1 | |
Soft tissue inflamation | ●In carrageenan-induced paw inflammation, 5-HT7 agonists reduce cyclooxygenase mRNA expression; decrease oxidative stress, serum cytokine levels |